Philogen S.p.A.
PHIL
Rank in Stocks
#10480
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Share Price
$23.85
Last synced: 2026-11-09
Market Cap
$688.74M
Change (1 day)
1.15%
Change (1 year)
-12.45%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Philogen S.p.A. (PHIL)
Category
Healthcare
EPS for Philogen S.p.A. (PHIL)
EPS as of June 2026 TTM: $6.20
According to Philogen S.p.A.'s latest financial reports, its current EPS (TTM) is $6.20. At the end of 2025 the company had an EPS of $6.69, an increase over its 2024 EPS of $1.17.
EPS history for Philogen S.p.A. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $6.20 | -7.32% |
| 2025 | $6.69 | 473.85% |
| 2024 | $1.17 | -802.90% |
| 2023 | $-0.17 | 18.94% |
| 2022 | $-0.14 | -69.36% |
| 2021 | $-0.45 | -16.99% |
| 2020 | $-0.55 | -1,120.48% |
| 2019 | $0.05 | -64.06% |
| 2018 | $0.15 | 45.61% |
| 2017 | $0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 152.57% |
US
|
|
| $-7.07 | -214.03% |
US
|
|
| $-5.29 | -185.32% |
AU
|
|
| $12.88 | 107.73% |
BE
|
|
| $21.56 | 247.73% |
NL
|
Questions about Philogen S.p.A.'s earnings per share (EPS)
What is Philogen S.p.A.'s earnings per share (EPS)?
Philogen S.p.A.'s earnings per share (EPS) over the last twelve months is $6.20, as of Jun 2026.
What was Philogen S.p.A.'s earnings per share (EPS) in 2025?
In 2025, Philogen S.p.A.'s earnings per share (EPS) was $6.69, 471.79% more than in 2024 ($1.17).
How has Philogen S.p.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Philogen S.p.A.'s earnings per share (EPS) was highest in 2025 ($6.69) and lowest in 2020 ($-0.55).
How does Philogen S.p.A.'s earnings per share (EPS) compare with similar companies?
Philogen S.p.A.'s earnings per share (EPS) ($6.20) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.